VOLUME 22 NUMBER 5 MAY 2015 nature structural & molecular biology a r t i c l e s RNA pol II elongation is blocked soon after initiation of transcription of many protein-coding genes, owing to the concerted action of the NTEFs, DRB sensitivity-inducing factor (DSIF) and negative elongation factor (NELF) [1] [2] [3] . The switch to productive elongation requires the activity of positive elongation factor b (P-TEFb), comprising CDK9 and a cyclin T. P-TEFb phosphorylates NELF, causing it to be released, and DSIF, converting it into a positive elongation factor 1-3 . P-TEFb also phosphorylates Ser2 of the 1-Tyr-Ser-Pro-Thr-Ser-Pro-Ser-7 repeat of the C-terminal domain (CTD) of the large subunit of pol II, to help recruit RNA-processing factors to emerging transcripts 4,5 . This potentially rate-limiting elongation 'checkpoint' can therefore hold back pol II to create a kinetic 'window of opportunity' for the recruitment of factors needed for RNA 5′ capping, productive elongation and RNA processing. In addition, this checkpoint facilitates the rapid and synchronous expression of genes during development 6 , and c-myc, NF-κB and HIV Tat recruit P-TEFb to activate transcription elongation 1 .
a r t i c l e s RNA pol II elongation is blocked soon after initiation of transcription of many protein-coding genes, owing to the concerted action of the NTEFs, DRB sensitivity-inducing factor (DSIF) and negative elongation factor (NELF) [1] [2] [3] . The switch to productive elongation requires the activity of positive elongation factor b (P-TEFb), comprising CDK9 and a cyclin T. P-TEFb phosphorylates NELF, causing it to be released, and DSIF, converting it into a positive elongation factor [1] [2] [3] . P-TEFb also phosphorylates Ser2 of the 1-Tyr-Ser-Pro-Thr-Ser-Pro-Ser-7 repeat of the C-terminal domain (CTD) of the large subunit of pol II, to help recruit RNA-processing factors to emerging transcripts 4, 5 . This potentially rate-limiting elongation 'checkpoint' can therefore hold back pol II to create a kinetic 'window of opportunity' for the recruitment of factors needed for RNA 5′ capping, productive elongation and RNA processing. In addition, this checkpoint facilitates the rapid and synchronous expression of genes during development 6 , and c-myc, NF-κB and HIV Tat recruit P-TEFb to activate transcription elongation 1 .
Pol II pausing also occurs at intron-exon junctions to facilitate recruitment of factors involved in splicing [7] [8] [9] , and a transcription checkpoint is associated with yeast prespliceosome formation 8 . In addition, pol II pausing at the end of the transcription unit is thought to couple 3′ processing to transcription termination 10, 11 .
We set out to elucidate the contribution of CDK9 to the control of transcription elongation genome wide in human HeLa cells. Our data indicate that productive elongation of the majority of pol II-transcribed human genes requires negotiation of a CDK9-dependent checkpoint early in the transcription cycle. Early-elongation checkpoints are generally (but not exclusively) located within ~200 bp of a transcription start site (TSS), and they occur whether or not pol II is paused close to the TSS. These results are consistent with the effect of CDK9 inhibitors in HEK293 cells 12 , mouse embryonic stem (mES) cells 13 and Drosophila 14 , and they emphasize that CDK9 is a critical kinase for transcription of metazoan pol II-transcribed genes.
Surprisingly, our analysis also revealed an additional major elongation control point close to the terminal poly(A) site, beyond which pol II cannot effectively proceed in the presence of CDK9 inhibitors. CTD phosphorylation associated with premature termination induced by the inhibitors is similar to the CTD phosphorylation pattern associated with normal termination downstream of the poly(A) site. The inhibitors also cause loss of association of CDK9, Spt5 and the poly(A) factors Ssu72 and CstF64, whereas association of the termination factor Pcf11 increases.
Kinase-dependent elongation checkpoints at terminal poly(A) sites provide a point late in the transcription cycle to regulate production of poly(A) mRNA and could, for example, facilitate rapid control of mRNA production from long genes in response to environmental signals and developmental cues.
RESULTS

KM and DRB inhibit transcription of GAPDH
To investigate the contribution of CDK9 to transcription elongation, we treated HeLa cervical adenocarcinoma cells with two drugs known to inhibit CDK9: KM05283 (KM) and 5,6-dichlorobenzimidazone-1-β-d-ribofuranoside (DRB) 15 for 15, 30, 45 and 60 min. In accordance with previous findings 16, 17 , these inhibitors caused loss of nascent transcripts from GAPDH, and inhibition was complete after 30 min of treatment ( Fig. 1a, Supplementary Fig. 1 and Supplementary Table 1) . Nascent transcripts from the 5′ external transcribed spacer (ETS) of pol I-transcribed rRNA genes and a pol III-transcribed tRNA gene were not adversely affected by the treatment (Fig. 1b) . These data are consistent with the inability of pol II to negotiate a TSS-proximal checkpoint when CDK9 is inhibited. CTD hyperphosphorylation (pol IIo) and phosphorylation (P) of CTD Ser2 were greatly reduced in cell extract after 30 min of drug treatment, whereas Ser5P was less affected (Fig. 1c) . Ser2P levels in the GAPDH gene body were also greatly reduced after 30 min of drug treatment, whereas Ser5P levels were not ( Fig. 1d and Supplementary Fig. 1c ). In conclusion, 30 min of drug treatment is sufficient for effective CDK9 inhibition.
CDK9 inhibitors globally affect early elongation
The role of P-TEFb in transcription-coupled RNA processing 4 precludes the use of steady-state RNA analysis to study the role of this complex in transcription. Accordingly, we mapped CDK9-reversible elongation checkpoints on pol II-dependent genes in HeLa cells with GRO-seq 18 coupled with KM and DRB treatment. GRO-seq allows the position and the orientation of engaged RNA polymerases to be mapped across the genome, providing a direct measure of transcription 18 .
We carried out GRO-seq 18 on nuclei isolated after 30 min of drug treatment, generated libraries of nascent RNAs and sequenced them with Illumina technology. We processed and normalized GRO-seq reads to reads in the 5′ ETS of the 45S rRNA gene (Fig. 1b and  Supplementary Fig. 2a-d ). The read profiles for two GRO-seq replicates of untreated (control) HeLa cells were very similar ( Supplementary  Fig. 2e-g ), and the results were consistent with those of a previous study using primary human lung fibroblast (IMR90) cells 18 . Also in line with this previous study 18 , the results of our metagene analysis indicated that most genes have a peak of GRO-seq reads, which corresponds to a peak of active paused pol II, close to the TSS in both sense and antisense directions. The sense peak is located 65 bp downstream of the TSS and the antisense peak 200 bp upstream ( Fig. 2a and Supplementary Fig. 2e,h) , locations similar to those of these peaks on genes in IMR90 cells 18 .
Treatment of cells with KM and DRB caused a notable increase of GRO-seq reads close to the TSS in both directions and loss of transcription within 500 bp of the TSS for the majority of genes (Fig. 2a) . This metagene profile is exemplified by the TRPM7 and DHX9 GRO-seq and pol II chromatin immunoprecipitation (ChIP) profiles, which showed an increase in the levels of both GRO-seq transcripts and pol II association close to the TSS (Fig. 2b,c and Supplementary  Fig. 3a,b) . Inhibition of transcription beyond a TSS-proximal checkpoint was reflected by a substantial increase in the metagene pausing index after drug treatment (Fig. 2d) . Antisense transcription upstream of TSSs was also globally restricted in a promoter-proximal manner by drug treatment (Fig. 2a) , a result indicating that antisense transcription is CDK9 dependent genome wide, in line with previous findings on individual genes 19 . The position of the sense (Fig. 2e) and antisense ( Supplementary Fig. 3c ) peaks relative to TSSs was the same before and after treatment, thus indicating that CDK9 inhibition reinforces TSS-proximal pausing without affecting the location of the pause. These results indicate that the drugs have a profound effect on the ability of newly initiated pol II to make the transition to productive elongation on protein-coding genes genome wide, presumably owing to inhibition of CDK9.
The promoter-proximal response to P-TEFb inhibitors varies Our metagene analysis (Fig. 2a) exemplified the most common profiles induced by the inhibitors but masked the behavior of genes with different profiles. Metagene analysis of the ratio of reads in untreated samples to those in treated samples in the first 5 kb of gene bodies gave negative values between −2 and −8 (Fig. 3a) . Thus, the number of reads in gene bodies dropped for all genes after treatment, but the relative drop varied for different genes. In TSS-proximal regions, this ratio varied from −2 to +2 (Fig. 3b) , thus indicating that the TSS-proximal peak diagnostic of pol II pausing is not always a r t i c l e s npg a r t i c l e s reinforced after treatment with KM and DRB. This is exemplified by the results of GRO-seq and pol II ChIP analysis of EIF2S3 (Fig. 3c,d ) and PLK2 ( Supplementary Fig. 4a,b) . In addition, not all genes had TSS-proximal pol II peaks before drug treatment (for example, CDKN1B, RPS14, RPS19 and DUSP1) (Fig. 3e) . However, the CDK9 inhibitors effectively abolished transcription in the bodies of these genes, a result indicating that TSS-proximal CDK9-dependent checkpoints also occur on genes without promoterproximal pausing (Fig. 3e) . Moreover, the response of pol II transcribing these genes was not uniform, with drug treatment causing either a marked increase in transcription close to TSSs (CDKN1B and RPS14) or a loss of reads close to TSSs and throughout the genes (RPS19 and DUSP1) (Fig. 3e) . There is therefore more than one flavor of response to P-TEFb inhibitors early in the transcription cycle.
The first sense checkpoint was also encountered relatively far (~1 kb) from the TSS in some genes, e.g., EIF2S3 (Fig. 3c,d ) and DHX9 Fig. 3a,b) . The drop of GRO-seq reads at this 'laterthan-normal' promoter-proximal elongation checkpoint is consistent with the loss of pol II ChIP signals (Fig. 3c,d and Supplementary  Fig. 3a,b) . Moreover, a drop in Ser2P levels occurred close to this 'late' promoterproximal elongation checkpoint on EIF2S3 ( Fig. 3d and Supplementary Fig. 4c ), rather than close to the TSS, as found for most genes, including PLK2 (Supplementary Fig. 4b ). In all cases, Ser5P was much less affected than Ser2P ( Supplementary Fig. 4b,c) . Although two TSSs could account for the two peaks of pol II at the beginning of EIF2S3, there is no evidence of this from transcript analysis or TATA-binding protein (TBP)-association studies (UCSC Genome Browser 2013).
(Supplementary
Our data indicate that a P-TEFb-dependent checkpoint early in the transcription cycle is a general pol II control mechanism but that the npg a r t i c l e s position of the checkpoint and the behavior of pol II in response to CDK9 inhibition is not uniform. In addition, our data indicate that pol II stalling in the absence of CDK9 inhibitors is neither necessary for nor diagnostic of a CDK9-dependent checkpoint early in transcription of human genes.
Uncovering a poly(A)-associated elongation checkpoint
Metagene analysis indicated that in the bodies of long genes, GRO-seq signals returned to control levels beyond ~20 kb after 30 min of KM and beyond ~50 kb after 30 min of DRB treatment ( Fig. 4a and Supplementary Fig. 5a ).
Pol II that has already negotiated the early-elongation checkpoint at the start of drug treatment can therefore continue transcription in the presence of CDK9 inhibitors. Transcription came back later in DRB-treated cells than in KM-treated cells, owing to differential rates of entry into the nucleus or differential effects of the two drugs on elongation rate. Considering that it may take DRB 5 to 10 min to enter the nucleus and to fully inhibit CDK9, pol II had traveled approximately 50 kb (Fig. 4a ) in 20-25 min without active CDK9. The elongation rate of pol II under these conditions would correspond to ~2-3 kb/min, which is within the range of measurements of elongation rate by other methods 13, 20, 21 .
In line with previous observations 18 , a broad sense peak was evident downstream of the poly(A) site in the absence of drug treatment ( Fig. 4b and Supplementary Fig. 5a ). This peak may reflect pol II pausing before termination 22, 23 . Unexpectedly, elongation of transcription beyond the poly(A) site was markedly reduced by the inhibitors, particularly KM, as shown by the metagene analysis of genes longer than 50 kb, whereas transcription upstream of the poly(A) site was unaffected (Fig. 4b) . A KM-and DRB-sensitive kinase is therefore required for elongation of transcription past the poly(A) site, in addition to the requirement for a KM-and DRBsensitive kinase early in the transcription cycle. These findings provide the first evidence, to our knowledge, of the existence of a poly(A)-associated checkpoint.
GRO-seq and pol II ChIP analysis of KPNB1 (Fig. 4c-e) and DHX9 ( Supplementary Fig. 5b,c) indicate that drug treatment did not affect the pol II levels upstream of the poly(A) site on these genes, whereas pol II levels at the poly(A) site and downstream were drastically reduced. The level of nascent transcripts past the poly(A) sites of KPNB1 and DHX9 was also drastically reduced ( Fig. 4f and Supplementary  Fig. 5c ). These results indicate that pol II prematurely terminated close to the poly(A) site, possibly as a result of CDK9 inhibition.
The differential effect of KM and DRB on the levels of pol II after the poly(A) site, both at the genome-wide level (Fig. 4b) and on KPNB1 and DHX9 (Fig. 4c,e and Supplementary Fig. 5b,c) , may reflect differential inhibition of CDK9 by the two drugs. Increasing the concentration of DRB decreased the amount of pol II transcribing past the KPNB1 poly(A) site (Fig. 4e) . In addition, 100 µM of KM and 200 µM DRB inhibited Spt5 phosphorylation more effectively than 100 µM DRB (Fig. 4g) . The CDK9 inhibitor flavopiridol 13 (Supplementary Fig. 5d ). However, it is also possible that these inhibitors affect kinases other than CDK9. For example, CDK12 is a Ser2 kinase that is recruited to the 3′ ends of protein-coding genes and is inhibited by flavopiridol in vitro [24] [25] [26] [27] . To assess the effect of more specific inhibition of CDK9, we ectopically overexpressed, in HEK293 cells, a form of CDK9 with the gatekeeper amino acid Phe103 mutated to an alanine to make the kinase sensitive to the analog 1-NA-PP1 (analog-sensitive CDK9 (CDK9AS)) 28 . After short interfering RNA-mediated knockdown of endogenous CDK9 ( Fig. 4h and Supplementary Fig. 5e ), CDK9AS represented the majority of cellular CDK9 (Supplementary Fig. 5f ). KM had the same effect on pol II levels on KPNB1 in both HeLa and HEK293 cells, and 1-NA-PP1 had no effect on transcription of KPNB1 in HEK293 cells when CDK9AS was not overexpressed (Fig. 4h and Supplementary Fig. 5g ). However, when CDK9AS was overexpressed, 1-NA-PP1 reduced the level of pol II after the poly(A) site (Fig. 4h) , thus suggesting that specific inhibition of CDK9 is at least partly responsible for the premature termination caused by KM, DRB and flavopiridol. Inhibition of CDK9AS by 1-NA-PP1 causes a less severe defect in elongation at both the beginning and the end of KPNB1 than KM, DRB or flavopiridol; this could be explained by some remaining endogenous CDK9 activity or incomplete inhibition of CDK9AS by 1-NA-PP1. Alternatively, additional kinases regulate transcription beyond the poly(A) site. The differential effects of KM and DRB at the 3′ ends of genes would therefore be due to differential inhibition of a kinase other than CDK9 that also has a role in the control of elongation at the ends of genes.
These data support the notion that CDK9 activity is required for efficient transcription through a poly(A)-associated elongation checkpoint to the normal end of the transcription unit, although other KM-, DRB-and flavopiridol-sensitive kinases may also be involved.
CTD phosphorylation and premature transcription termination
Termination of transcription induced by CDK9 inhibitors is probably caused by premature release of elongation factors or premature recruitment of termination factors. The CTD of pol II acts as a platform to recruit various factors involved in transcriptional and cotranscriptional events, and its properties are modulated by posttranslational modifications 5 . Changes in the CTD-modification pattern caused by drug treatment may therefore be associated with premature termination. In the absence of CDK9 inhibitors, Ser2P and Thr4P increased toward the 3′ end of KPNB1, and Ser5P and Tyr1P were enriched at both the 5′ and 3′ ends, whereas Ser7P was quite constant along the gene (Fig. 5 and Supplementary Fig. 6a,b) . These results are in line with genome-wide analyses for these modifications 29, 30 . When normalized to the pol II level, Tyr1P, Ser2P and Thr4P were higher after the poly(A) site than immediately before it, and Ser5P decreased, whereas Ser7P levels remained the same (Supplementary Fig. 6a,b) .
Changes in the CTD phosphorylation pattern on KPNB1 after drug treatment can be investigated only when the level of pol II is detectable (Figs. 4e and 5 and Supplementary Fig. 6a ). The cellular levels of Tyr1P, Thr4P and Ser7P were not drastically affected by the drugs (Supplementary Fig. 6c ). The level of Ser2P before the poly(A) site was also not markedly affected by the drugs, whereas Ser5P decreased before the poly(A) site, with 100 µM KM causing a greater effect than 100 µM DRB. Ser7P increased with both drugs. The peaks of Tyr1P and Thr4P downstream of the poly(A) site in the absence of CDK9 inhibition were shifted upstream of the poly(A) site by drug treatment. The increase in the levels of Tyr1P and Thr4P upstream of the poly(A) site was greater after 100 µM KM treatment than 100 µM DRB treatment, a result suggesting that the increase in these modifications is somehow associated with premature termination.
Thus, the CTD of pol II associated with premature termination is phosphorylated on Tyr1, Ser2, Thr4, Ser5 and Ser7. This closely mirrors the signature of CTD phosphorylation on pol II before termination downstream of a functional poly(A) site, thus suggesting that common mechanisms are involved in these termination processes.
Recruitment of poly(A) and elongation factors
Four major complexes are involved in recognition of the poly(A) site and RNA cleavage: cleavage and polyadenylation-specific factor (CPSF), cleavage-stimulatory factor (CSTF), cleavage factor I and cleavage factor II 31 .
The Pcf11 component of cleavage factor II is required for termination in vivo 32 , and it promotes pol II release from template DNA in vitro 33, 34 . The peak of Pcf11association shifted from downstream to upstream of the poly(A) site after drug treatment (Fig. 6a,b and Supplementary Fig. 7 ). Pcf11 could therefore be involved in premature termination caused by CDK9 inhibitors. However, Pcf11 knockdown induced a termination defect, as expected 32 , but did not prevent KM-mediated premature termination (Fig. 6c) .
Ssu72 Ser5P phosphatase (a subunit of the CPSF complex), CstF64 (a subunit of the CSTF complex), CDK9 and Spt5 were all lost from the KPNB1 poly(A)-site region after treatment with KM or npg a r t i c l e s DRB ( Fig. 6d and Supplementary Fig. 7) , thus implicating these factors in transcription past the poly(A) site. The cellular levels of these factors were not adversely affected (Supplementary Fig. 6c ).
Loss of Ssu72 and Cstf64 suggests that polyadenylation of transcripts is affected by the inhibitors. Loss of CDK9 and Spt5 suggests that Spt5 and its phosphorylation by CDK9 may be critical to negotiate a transcription checkpoint close to the poly(A) site at the functional ends of protein-coding genes.
DISCUSSION
Our characterization of the contribution of CDK9-dependent steps to the control of transcription in human cells has defined kinasedependent checkpoints close to the TSSs of pol II-transcribed genes in both sense and antisense directions genome wide. Our analysis has also revealed a hitherto-unexpected kinase-dependent transcriptionelongation checkpoint near the ends of genes.
The role of P-TEFb early in the transcription cycle
The development of genome-wide GRO-seq has allowed actively engaged pol II to be distinguished from unengaged pol II at the 5′ ends of genes 18 . This technique therefore facilitates a more accurate characterization of pol II behavior immediately after initiation. Our results of GRO-seq combined with a short treatment of cells with CDK9 inhibitors indicate that the majority of human protein coding-type genes analyzed, including those for long noncoding RNAs (e.g., Malat), have a CDK9-dependent promoter-proximal elongation checkpoint. Our findings are in agreement with the large amount of in vitro and in vivo data indicating that CDK9 inhibitors have a drastic effect on pol II transcription [1] [2] [3] [12] [13] [14] . In addition, most, but not all, protein codingtype genes also have CDK9-sensitive antisense transcription initiating in their TSS regions. Thus, pol II initiating in either direction comes under the control of NTEFs, and this suggests that their recruitment is linked to initiation of transcription of this type of gene. Our results are consistent with the results of other genome-wide studies using CDK9 inhibitors in human, mouse and Drosophila cells [12] [13] [14] .
Productive elongation of genes with no obvious pol II pausing is CDK9 dependent. The lack of promoter-proximal pausing therefore does not mean that an early-elongation checkpoint is absent but rather that initiation and the transition to productive elongation are balanced. Our data also indicate that promoter-proximal checkpoints can be located further than 200 bp downstream of TSSs. The exact response of pol II to CDK9 inhibitors at the beginnings of genes and the position of the checkpoint is likely to depend on the complex kinetic interplay of pol II, transcription factors, P-TEFb and NTEFs on each gene. For example, if NELF and/or DSIF are recruited slowly relative to the speed of pol II, the checkpoint will occur further from the TSS, as has been shown for pol II pausing in Drosophila 35 . Our data are therefore consistent with the notion that P-TEFb activity is a general requirement for productive elongation of mammalian genes, whether or not pol II is obviously paused after initiation.
Transcription elongation in the absence of active CDK9
Our results and those of a previous study 13 , indicate that pol II continues elongation of transcription in both HeLa and mES cells in the presence of CDK9 inhibitors. Thus, the continued activity of CDK9 appears to be dispensable for transcription once the early-elongation checkpoint has been passed. CDK9 phosphorylates the Nelf-E subunit of NELF, the Spt5 subunit of DSIF and Ser2 of the pol II CTD heptapeptide. NELF is found associated only with the beginnings of genes because it is released from the elongation complex after phosphorylation 36 . We detected phosphorylation of Ser2 of the CTD of elongating pol II after treatment of cells with CDK9 inhibitors, and hence we argue that this mark persists or is placed by a kinase unaffected by the drugs. It is likely that some Spt5 phosphorylation persists up to the point of premature termination in the presence of the inhibitors, because Spt5P is an important elongation factor for pol II after the early-elongation checkpoint 37, 38 .
After pol II transcribes a poly(A) site, it pauses to allow cleavage and polyadenylation of the nascent transcript, and this is followed by termination of transcription 11 . The finding that treatment with CDK9 inhibitors causes pol II to prematurely terminate transcription close to the poly(A) site genome wide was unexpected. The drop, caused by CDK9 inhibitors, in the levels of both CDK9 and Spt5 associated with the region of the poly(A) site is consistent with the notion that Spt5 and its phosphorylation by CDK9 is required for efficient transcription beyond the poly(A) site. 
CTD phosphorylation and termination of transcription
The pattern of CTD phosphorylation associated with premature termination in response to CDK9 inhibition is similar to CTD phosphorylation of pol II terminating downstream of a poly(A) site, particularly with respect to the peak of Tyr1P and Thr4P and the decrease of Ser5P 29, 30 . This pattern of phosphorylation could be a cause or consequence of termination. For example, a premature increase in phosphorylation of Tyr1 and/or Thr4 could cause release of necessary elongation factors or premature recruitment of termination factors. We were surprised to find Tyr1P at both ends of KPNB1 because this modification is specifically associated with the bodies of yeast genes 39 . However, a recent paper has shown that phosphorylation of Tyr1 is associated with the 5′ and 3′ ends of mammalian genes genome wide 30 . In yeast, Tyr1P helps to recruit and/or stabilize binding of the elongation-associated factor SPT6 and to inhibit binding of the termination factors Pcf11 and Rtt103 (ref. 39) . We find that the increase in Tyr1P at the 3′ end of KPNB1 correlates instead with an increase in Pcf11 recruitment and premature termination rather than a termination defect. These results emphasize a clear difference in the effect of Tyr1P on Pcf11 recruitment in yeast and human cells. The increase in Ser7P caused by CDK9 inhibitors could be due to loss of Ssu72, which has been shown to dephosphorylate Ser7P 40 .
Effect of CDK9 inhibitors on poly(A) site-associated factors
Premature termination near poly(A) sites is accompanied by loss of the poly(A) factors Ssu72 and CstF64. CstF64 recognizes the less conserved U-or GU-rich sequence located 30 nt downstream of the cleavage site of the poly(A) signal 31 . Ssu72 is a component of CPSF, and the yeast homolog has CTD Ser5P and Ser7P phosphatase activity 40, 41 . Loss of these factors suggests that no functional poly(A) site is available, and consequently no functional polyadenylation complex is formed.
Pcf11 is required for termination in vivo, and it facilitates premature termination of transcription of HIV templates 32, 42 . The increase in the level of Pcf11 upstream of poly(A) sites after CDK9 inhibition is, however, not necessary for premature termination. The loss of CDK9 and Spt5 from the end of the KPNB1 gene in response to drug treatment provides a mechanistic explanation for the failure of pol II to efficiently elongate to the point of normal termination.
The poly(A)-associated elongation checkpoint
Our data support the model that phosphorylation of one or more targets of CDK9 is required for pol II to efficiently elongate beyond a poly(A) site. Targets of CDK9 involved in regulation of transcription include Ser2 of the pol II CTD, the Nelf-E subunit of NELF and the Spt5 subunit of DSIF. The levels of Ser2P upstream of poly(A) sites are not affected by drug treatment, and Nelf-E is not present at the ends of genes 36 . Spt5 instead is detected at the ends of genes genome wide 36 . This raises the possibility that phosphorylation of Spt5 is required for transcription through both the early-elongation checkpoint and the poly(A)-associated checkpoint. In support of this notion, 100 µM KM more effectively inhibits phosphorylation of Spt5 and the association of Spt5 upstream of the KPNB1 poly(A) site than 100 µM DRB; this could account for the differential effect of these inhibitors on transcription beyond the poly(A) site. Our analysis does not exclude the possibility that kinases other than CDK9 are inhibited by the drugs. Although inhibition of CDK9AS affects elongation of transcription at both the beginning and end of KPNB1, KM causes transcription to terminate further upstream from the poly(A) site, a result implicating additional KM-sensitive kinases in transcription through a poly(A)-associated checkpoint.
Our current working model (Fig. 7) is that inhibition of CDK9, and possibly additional kinases, causes loss of CDK9 and Spt5P near poly(A) sites, thus compromising the elongation efficiency of pol II. Additionally, specific loss of other elongation factors in this region of genes 43 and/or recruitment of termination factors 10,11 through, for example, alterations in pol II CTD modification may cause pol II to terminate prematurely close to poly(A) sites.
Soon after pol II transcribes a legitimate poly(A) signal, the commitment to make a viable mRNA becomes irreversible if all the necessary splicing and polyadenylation factors are available, reaching the point of no return. A kinase-regulated poly(A)-associated transcription-elongation checkpoint therefore constitutes a powerful final control mechanism at the level of transcription to halt production of processed mRNA.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
Cell culture and transient transfection. HeLa and HEK293 cells were grown in DMEM supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM l-glutamine, at 37 °C and 5% CO 2 . HeLa cells were treated with 100 µM KM05283 (Maybridge), 100 µM or 200 µM DRB (Sigma) or 1 µM flavopiridol (Sanofi) as indicated.
For ectopic expression of CDK9AS, a pcDNA3 vector encoding CDK9AS with three myc epitope tags at the C terminus (Supplementary Fig. 6a ) was cotransfected into HEK293 cells (~7 × 10 6 ), together with a pcDNA3 vector encoding cyclin T1, a pLKO.1 vector encoding CDK9 shRNA (Sigma) or a control plasmid conferring puromycin resistance, with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Cells were treated with neomycin (0.4 mg/ml) and puromycin (3 µg/ml) to select transfected cells. Selected cells were treated for 30 min with 10 µM 1-NA-PP1. As a negative control, HEK293 cells were cotransfected with empty pcDNA3 conferring neomycin resistance.
siRNAs targeting Pcf11 (Dharmacon siGENOME SMART pool) were transfected into HeLa cells with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions, for 48 h, and cells were treated with 100 µM KM for 30 min.
RNA preparation. RNA was extracted from 6 × 10 6 control or KM/DRB-treated HeLa cells with TRIzol (Invitrogen), according to the manufacturer's instructions. Reverse transcription (RT) was performed with 1 µg of RNA and random hexamers with the SuperScriptIII kit (Invitrogen), according to the manufacturer's instructions. cDNA was amplified by qPCR with a QuantiTect SYBR Green PCR kit (Qiagen). The level of 7SK RNA was used to normalize the samples. Experiments were replicated three times to ensure reproducibility, and each RNA sample was measured in triplicate by qPCR. The sequence of primers is given in Supplementary Table 1. Chromatin immunoprecipitation (ChIP). ChIP analysis was performed as previously described 45 Table 1 . Experiments were replicated three times to ensure reproducibility, and each ChIP sample was measured in triplicate by qPCR.
Western blot. Western blot analysis was performed as previously described 46 with approximately 30 µg of proteins from cells boiled in Laemmli buffer (50 mM Tris, pH 6.8, 2% sodium dodecyl sulfate, 5% β-mercaptoethanol, 10% glycerol, and 0.1% bromophenol blue), and antibodies against pol II (sc-9001, Santa Cruz), pSer2 (Ab5095, Abcam), pSer5 (ab5131, Abcam), mitotic phosphoproteins/CC3 (ab78272, Abcam), which recognizes Spt5P 44 , Spt5 (sc-28678, Santa Cruz), α-tubulin (200-301-880, Rockland), actin (sc-1615, Santa Cruz), Pcf11 (A303-706A, Bethyl Laboratories), Tyr1P (61384, Active Motif), Thr4P (61362, Active Motif), Ser7P (61088, Active Motif), Cstf64 (A301-092A, Bethyl Laboratories) and CDK9 (sc-484, Santa Cruz). Validation for all antibodies is provided on the manufacturers' websites.
Global run-on sequencing (GRO-seq). 1.5 × 10 7 HeLa cells treated or not with 100 µM KM or 100 µM DRB for 30 min were harvested by centrifugation, washed with PBS, and resuspended in HLB (10 mM Tris, pH 7.5, 10 mM NaCl, and 2.5 mM MgCl 2 ) with 0.5% NP-40, and 2 U/ml SUPERase In (Ambion). After 5 min incubation on ice, nuclei were pelleted through a cushion of HLB, 0.5% NP-40, 10% sucrose, and 2 U/ml SUPERase In. Nuclei were resuspended in an equal volume of transcription buffer (10 mM Tris, pH 8, 5 mM MgCl 2 , 1 mM DTT, 300 mM KCl, 20U SUPERase In, 1% sarkosyl, 500 µM ATP, GTP and Br-UTP, and 2 µM CTP). The transcription reaction was carried out at 30 °C for 5 min and terminated by centrifugation for 30 s. Nuclei were resuspended in HSB (10 mM Tris, pH 7.5, 0.5 M NaCl, and 10 mM MgCl 2 ) containing 10 U of RNase-free DNase and were incubated at 30 °C for 20 min. Protein was digested by the addition of 200 µg/ml of proteinase K in buffer (20 mM Tris-HCl, pH 7.4, 2% SDS, and 10 mM EDTA) at 55 °C for 1 h. RNAs were extracted twice with acid phenol/chloroform and once with chloroform and were precipitated with three volumes of −20 °C ethanol containing 30 mM NaCl and glycogen. The pellet was washed with 75% ethanol before resuspension in 20 µl of DEPC-treated water. Base hydrolysis, immunoprecipitation of Br-U RNA and end repair were performed as previously described 18 . The run-on library was prepared by the High-Throughput Genomics Group at The Wellcome Trust Centre for Human Genetics and was sequenced with Illumina HiSeq.
would be 10 kb in length. For calculation of the signal in different transcript segments, only the 5′ end of each read was counted and 5′-ETS normalized. Considering the short time of drug treatment and the resulting recovery of signal on long genes, a transcription level for each transcript was scored between +1 kb and +6 kb downstream of the TSS (gene body). To locate and quantify TSSproximal peaks, an interval of 1 kb upstream and downstream of the annotated TSS was scanned with a 100-bp sliding window. The location of the maximum signal and its 5′-ETS-normalized read density was identified. Pausing index was calculated as a ratio of signal in the TSS-proximal peak and average read density in the 5-kb gene body. The transcription-termination profile was quantified with a ratio of normalized read counts in the 2-kb intervals downstream and upstream of the annotated transcript end, which corresponds to the terminal poly(A). npg
